Secondary Prevention Strategies for Heart Failure with Diabetes and CKD

Introduction to Secondary Prevention

• The American College of Cardiology recommends secondary prevention in established heart failure, focusing on reducing mortality, preventing hospitalizations, and improving quality of life through aggressive symptom management and disease-modifying therapies 1, 3.

Pharmacological Interventions

• The American Heart Association suggests initiating SGLT2 inhibitors immediately as they provide proven benefits across the cardiorenal-metabolic spectrum in patients with heart failure, diabetes, and CKD, reducing heart failure hospitalizations, cardiovascular death, and slowing CKD progression 1, 5.
• The National Kidney Foundation recommends initiating and titrating RAS blockade (ACEi or ARB) to maximum tolerated dose in patients with diabetes, hypertension, and albuminuria, monitoring serum creatinine and potassium within 2-4 weeks of initiation or dose changes 1, 2, 3.
• The American Diabetes Association advises statin therapy for all patients with diabetes and CKD, regardless of baseline lipid levels, to reduce cardiovascular events and mortality in this high-risk population 1.

Additional Therapies

• The European Society of Cardiology suggests considering GLP-1 receptor agonists as alternative or addition if SGLT2 inhibitors are insufficient, contraindicated, or not tolerated, providing cardiovascular benefits in patients with diabetes and high CV risk 1.
• The American College of Cardiology recommends antiplatelet therapy, such as aspirin, for secondary prevention in patients with established cardiovascular disease, balancing against bleeding risk, particularly with low GFR 3, 6, 7.

Lifestyle Modifications and Monitoring

• The American Heart Association recommends exercise, nutrition counseling, and smoking cessation as foundational interventions for all patients, complementing pharmacotherapy in established disease 1, 3, 6.
• Regular reassessment every 3-6 months of all cardiovascular and metabolic risk factors, monitoring kidney function, electrolytes, and adjusting medications as CKD progresses, is advised by the National Kidney Foundation 1, 3.